Bibliometric analysis of toll-like receptor agonists associated with cancer therapy

Wei Li1, Li Wan1, Shaojun Duan2

  • 1Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Medicine
|January 14, 2022
PubMed
Abstract

Insights

This bibliometric analysis reveals key trends in Toll-like receptor (TLR) agonist research. The field evolved from understanding TLR signaling mechanisms to discovering and applying TLR agonists for immunotherapy and vaccine development.

Area of Science:

  • Immunology
  • Pharmacology
  • Bibliometrics

Background:

  • Toll-like receptors (TLRs) are innate immune system pattern-recognition receptors targeted for antitumor strategies.
  • Numerous TLR agonists have been developed as immunotherapeutics and vaccine adjuvants.
  • Bibliometric analysis provides insights into the research landscape of TLR agonists.

Purpose of the Study:

  • To analyze the publication output, key journals, leading countries, institutions, and authors in TLR agonist research.
  • To identify research hotspots and evolution trends in the field of TLR agonists.
  • To provide a bibliometric overview of TLR agonist research from 2000 to 2019.

Main Methods:

  • Collected 1914 articles on TLR agonists from the Web of Science Core Collection (2000-2019).
  • Analyzed publication data using VOSviewer and CiteSpace software.
  • Examined publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, hotspots, and trends.

Main Results:

  • The USA led in publications and international collaboration; The Journal of Immunology published the most articles.
  • University of Minnesota and University of Pennsylvania were leading institutions; Gudkov AV and Akira Shizuo were highly productive/cited authors.
  • Research trends shifted from TLR signaling mechanisms (2000-2010) to agonist discovery (2011-2014) and then to therapeutic applications (2015-2019).

Conclusions:

  • Bibliometric analysis offers a comprehensive landscape of TLR agonist research.
  • The study highlights the dynamic evolution of TLR agonist research, from basic mechanisms to clinical applications.
  • This overview aids researchers in understanding the current status and future directions in the field.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K